Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The mitochondrial translational initiation factor 3 pseudogene (ENSG00000214278; LOC100310782) is classified as a **pseudogene**, meaning it is a nonfunctional segment of DNA similar to a functional gene (in this case, the mitochondrial translation initiation factor 3, MTIF3) but does not encode a functional protein product[1][2][3][5]. Pseudogenes generally arise from duplication or retrotransposition events but accumulate mutations over time that disrupt their ability to produce protein[4]. While some pseudogenes can have regulatory roles at the RNA level (such as acting as competitive endogenous RNAs or sources of small interfering RNAs), there is currently no evidence that LOC100310782 functions as a protein-coding gene or a therapeutic target; it is not considered a receptor, enzyme, or druggable entity[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mitochondrial translational initiation factor 3 pseudogene.